Business Model & Revenue
Starling Oncology is one of the largest value-based community oncology groups in the United States, serving approximately 2.1 million patients across 100+ clinics and network locations in five states. Formerly known as The Oncology Institute, the company rebranded in 2026 to Starling Oncology.
Revenue Streams:
- Patient Services — Fee-for-service oncology care, infusion services, clinical visits
- Specialty Pharmacy — In-house pharmacy dispensing oncology drugs (58% revenue growth in Q2 2026 on record Part D fills)
- Capitated/Value-Based Contracts — Fixed per-member-per-month payments for oncology benefit management; approximately $150M expected in 2026
- Clinical Trials & Other — Research partnerships and ancillary services
Value-Based Model: Starling takes responsibility for total cancer care costs in exchange for fixed capitated payments from Medicare Advantage and commercial payers. The company manages costs through evidence-based clinical pathways, in-house specialty pharmacy, and care coordination. Capitated revenue carries higher margins than fee-for-service and is recurring.
Q2 2026 Operational Highlights:
- Achieved exclusivity in California with one of its largest partners across all delegated medical groups (+230K lives)
- First delegated contracts outside Florida: Nevada and Oregon
- Specialty Pharmacy Part D fills hit record levels
- Launching Starling Oncology Nexus provider portal in August 2026
Financial Highlights
Q2 2026 vs Q2 2025 Comparison
| Metric | Q2 2026 | Q2 2025 | YoY Change |
|---|---|---|---|
| Revenue | $161.3M | $119.8M | +34.6% |
| Gross Profit | $27.2M | $17.5M | +55.2% |
| Gross Margin | 16.9% | 14.6% | +230 bps |
| Net Loss | ($9.8M) | ($17.0M) | 42% improvement |
| EPS | ($0.08) | ($0.15) | 47% improvement |
| Adjusted EBITDA | $0.2M | ($4.1M) | Turned positive |
Quarterly Progression
| Quarter | Revenue | Net Loss | Adj. EBITDA | Gross Margin |
|---|---|---|---|---|
| Q2 2025 | $119.8M | ($17.0M) | ($4.1M) | 14.6% |
| Q4 2025 | $142.0M | ($7.5M) | $0.1M | 16.0% |
| Q1 2026 | est. $147M | est. ($9.6M) | est. $0.1M | est. 16.5% |
| Q2 2026 | $161.3M | ($9.8M) | $0.2M | 16.9% |
Balance Sheet (June 30, 2026)
| Item | Jun 2026 | Dec 2025 |
|---|---|---|
| Cash | $41.1M | $33.6M |
| Stockholders' Equity | improving | ($15.7M) |
| Shares Outstanding | approx. 123M | 98.9M |
Updated FY2026 Guidance:
- Revenue: $650-670M (raised from $630-650M; +9-12% vs original)
- Gross Profit: $105-110M (raised from $97-107M)
- Adjusted EBITDA: $2-7M (narrowed from $0-9M)
- Free Cash Flow: $5-15M (unchanged)
- Capitated Revenue: approximately $150M
Q3 2026 Outlook: Adjusted EBITDA of $0.5-1.5M as Florida delegated lives ramp
Competitive Landscape
Starling operates in the fragmented oncology services market, competing with national networks and regional community practices. The value-based care niche has fewer direct competitors.
Key Competitors:
- US Oncology Network (McKesson): Largest community oncology network; approximately 1,400 physicians; franchise model limits operational control
- OneOncology: PE-backed platform; approximately 1,000 physicians; aggressive acquisition growth
- GenesisCare: Global oncology provider; filed Chapter 11 in 2023, restructured
- Regional Health Systems: Hospital-employed oncologists; captive referrals but higher cost structures
- Memorial Sloan Kettering / MD Anderson: Academic centers; premium pricing, limited geographic reach
Moats:
- Capitated Contract Portfolio — approximately $150M 2026 capitated revenue with Elevance, Humana, CarePlus; hard to replicate
- Clinical Pathways — Evidence-based protocols with 15+ years of outcome data
- Scale in Community Setting — 100+ clinics, 400+ employed and network clinicians, 2.1M covered lives
- Exclusivity Agreements — California exclusivity deal removes a competitor and consolidates 230K lives
- Technology Platform — Starling Nexus portal deepens provider engagement and pathway adherence
Catalysts
-
Florida delegated lives ramp (H2 2026) — Q3 guidance of $0.5-1.5M Adj. EBITDA assumes successful onboarding; beat could drive re-rating
-
Additional capitated contract wins — Nevada and Oregon entries prove the model travels beyond Florida; more states likely in 2027
-
Starling Nexus portal launch (August 2026) — Proprietary provider portal should improve pathway adherence and Medical Loss Ratio management
-
Sustained EBITDA positivity — Q2 was the second positive Adjusted EBITDA quarter; sustained profitability in H2 could attract institutional buyers
-
Potential for positive GAAP net income in 2027 — Net loss narrowed 42% in Q2; the trajectory suggests GAAP breakeven within 4-6 quarters
Key Risks
- Seasonality impacts — Q1 typically weakest due to deductible resets and drug pricing lags
- Payer concentration risk — Elevance partnership represents significant capitated revenue
- Negative book value — stockholders' equity deficit limits financial flexibility
- Regulatory risk — Medicare Advantage and Part D reimbursement changes could pressure margins
- Execution risk — raised guidance assumes continued capitated contract wins and Florida ramp
Our Thesis
Starling Oncology is proving that value-based oncology care scales profitably. Revenue grew 35% in Q2 with Adjusted EBITDA turning positive for the second consecutive quarter — the operational inflection we flagged in March is accelerating. Specialty Pharmacy revenue surged 58% as new capitated lives drove prescription volume. The California exclusivity deal (adding 230K lives) and first out-of-Florida contracts (Nevada, Oregon) expand the capitated revenue engine that drives high-margin, recurring growth. The Starling Nexus provider portal launching in August should further strengthen clinical pathway adherence.
At $499M market cap, STLN trades at 0.75x updated 2026 revenue guidance midpoint ($660M) — still cheap for a company growing revenue 35% with improving margins. Our $8.00 PT applies a 10x multiple to the $4.5M midpoint of updated 2026 Adjusted EBITDA guidance ($2-7M), plus a growth premium for the $150M capitated revenue stream and 2.1M covered lives. This remains a Bullish rating; the primary risk is executing on Florida delegated lives ramp in H2.
Get reports like this delivered free
New small-cap research every week. No paywall, no fluff.